Tamoxifen-induced DNA adducts in endometrial samples from breast cancer patients.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 8813128.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Tamoxifen-induced DNA adducts were analyzed with the (32)P-postlabeling method using high-performance liquid chromatography (HPLC)-radioactivity detection from endometrial tissue of breast cancer patients and controls. Liver DNA from tamoxifen-treated rats was used as a positive standard. In blind analysis, five of the seven samples from tamoxifen-treated patients showed DNA adducts; none of the five controls were positive. The identity of the tamoxifen adduct was confirmed by using different chromatographic systems, isolating the HPLC fractions and running them on TLC, with or without spiked rat liver samples. The level of adducts in the treated patients was 2.7 adducts/10(9) nucleotides in the HPLC analysis.
Medical subject headings
- Antineoplastic Agents, Hormonal
- Breast Neoplasms
- Carcinogens
- DNA Adducts
- DNA Damage
- Endometrium
- Estrogen Antagonists
- Tamoxifen